Welcome to our dedicated page for RTSLD news (Ticker: RTSLD), a resource for investors and traders seeking the latest updates and insights on RTSLD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RTSLD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RTSLD's position in the market.
DALLAS, March 21, 2023 (GLOBE NEWSWIRE) -- Rapid Therapeutics Science Laboratories (OTC: RTSL) is optimistic following the OMB’s clearance of FDA guidance on cannabis clinical research. This guidance may pave the way for how cannabis-derived products are regulated. CEO Donal Schmidt expressed enthusiasm regarding the potential for CBD products to be recognized as drugs, anticipating IND submission for their CBD Metered Dose Inhaler by Q3 2023. The company's annual 10K filing is on schedule, and they are working on a re-IPO with Nasdaq. Additionally, the corporate website is undergoing a revamp after being hacked. RTSL aims to strengthen its position in the cannabis market.
Rapid Therapeutics Science Laboratories (OTC: RTSL) has transitioned three proprietary pharmaceutical grade patents from provisional to non-provisional status, focusing on inhalation formulations of CBD and CBG. CEO Donal R. Schmidt, Jr. anticipates FDA approval for these products via pressurized metered dose inhalers. Previously, RTSL marketed these cannabinoids but shifted its strategy towards research and regulatory approval. Further patent applications, including THC-based inhalants, are expected soon. RTSL emphasizes ongoing FDA compliance and product development, continuing its commitment to biopharmaceutical innovation.
Rapid Therapeutics Science Laboratories (OTC: RTSL) announced its S1 filing and mid-year strategy review on July 26, 2022. CEO Donal Schmidt emphasized the company's focus on pharmaceutical R&D and aerosol technology to enhance natural relief solutions. The company aims to file an investigational new drug application (IND) for its CBD metered dose inhaler (MDI) with the FDA. Despite CBD's legal status in many states, it is not FDA-approved for consumption. RTSL remains committed to research and development in biologics while seeking a major stock exchange listing.
Rapid Therapeutics Science Laboratories (OTC: RTSL) has announced its participation in the Respiratory Drug Delivery (RDD) 2022 Conference from May 1-5, 2022, in Orlando, Florida. The conference is recognized globally in the respiratory field, influencing key regulatory and scientific policies. RTSL focuses on natural relief innovations through aerosol delivery, including pressurized metered dose inhalers (pMDI) containing patent-pending cannabinoid compounds. The company is preparing to submit an investigational new drug application (IND) to the FDA for its CBD MDI.
FAQ
What is the market cap of RTSLD (RTSLD)?
